MSD has gauged its financial hit from Trump tariffs

MSD has gauged its financial hit from Trump tariffs

MSD expects to see an additional $200m layered onto its costs this year as a result of President Trump's tariffs, ahead of any pharma-specific levy.

Merck takes $200M tariff hit, trimming its gross profits

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.

Live: American pharmaceutical company Merck said on Thursday that it expects...

MSD’s Gardasil sales slide further due to China constraints - Pharmaceutical Technology

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.